Drug History: LAMICTAL

DRUGS THAT CAUSES A FALSE POSITIVE ON A DRUG TEST

Browse by Letter: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Label and Approval History

Drug Name:	LAMICTAL
FDA Application No:	(NDA) 020241
Active Ingredient(s):	LAMOTRIGINE
Company:	GLAXOSMITHKLINE

Label History

View the label approved on September 25, 2006 for LAMICTAL, (NDA) 020241

To see older, previously-approved labels, go to the "Approval History" section of this page. Older labels are for historical information only and should not be used for clinical purposes.

Approval History

Action Date	Supplement Number	Approval Type	Letters, Reviews, Labels, Patient Package Insert
3/17/2006	029	Labeling Revision
9/22/2006	027	New or Modified Indication	Letter Label Label
9/25/2006	027	Labeling Revision	Letter Label Label
9/22/2006	026	New or Modified Indication	Letter Label Label
9/25/2006	026	Labeling Revision	Letter Label Label
9/22/2006	025	New or Modified Indication	Letter Label
9/25/2006	025	Labeling Revision	Letter Label
9/22/2006	021	New or Modified Indication	Letter Label Label
9/25/2006	021	Labeling Revision	Letter Label Label
4/4/2003	018	Labeling Revision	Letter
6/20/2003	017	New or Modified Indication	Letter Label Review
1/14/2004	016	Efficacy Supplement with Clinical Data to Support	Letter
2/23/2001	015	Labeling Revision
9/8/2000	014	Labeling Revision
6/12/2000	012	Manufacturing Change or Addition
5/25/2001	011	Efficacy Supplement with Clinical Data to Support	Label Review
9/22/2006	010	New or Modified Indication	Letter Label Label
9/25/2006	010	Labeling Revision	Letter Label Label
6/8/1999	009	Manufacturing Change or Addition
1/17/2003	008	New or Modified Indication	Label
5/10/1999	007	Manufacturing Change or Addition
3/16/1998	006	Labeling Revision
3/16/1998	005	Control Supplement
3/11/1997	004	Labeling Revision
12/14/1998	003	New or Modified Indication	Letter Label Review Dear Health Professional Letter
8/24/1998	002	New or Modified Indication	Letter Label Review Dear Health Professional Letter
12/27/1994	000	Approval	Other Important Information from FDA

Therapeutic Equivalents